Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial

Viola Klück, Tim Jansen, M. Janssen, Antoaneta Comarniceanu, M. Efdé, Isak W. Tengesdal, Kiki Schraa, Maartje C. P. Cleophas, Curtis L. Scribner, Damaris B. Skouras, Carlo Marchetti, Charles A. Dinarello, Leo A. B. Joosten